BR112013015957B1 - Uso de naltrexona ou um sal farmaceuticamenteaceitável da mesma e bupropiona ou um salfarmaceuticamente aceitável da mesma, composiçãofarmacêutica e kit - Google Patents

Uso de naltrexona ou um sal farmaceuticamenteaceitável da mesma e bupropiona ou um salfarmaceuticamente aceitável da mesma, composiçãofarmacêutica e kit Download PDF

Info

Publication number
BR112013015957B1
BR112013015957B1 BR112013015957-0A BR112013015957A BR112013015957B1 BR 112013015957 B1 BR112013015957 B1 BR 112013015957B1 BR 112013015957 A BR112013015957 A BR 112013015957A BR 112013015957 B1 BR112013015957 B1 BR 112013015957B1
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
naltrexone
acceptable salt
bupropion
binge eating
Prior art date
Application number
BR112013015957-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013015957A2 (pt
Inventor
Susan McElroy
Eduardo Dunayevich
Ron Landbloom
Original Assignee
Nalpropion Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013015957(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nalpropion Pharmaceuticals Llc filed Critical Nalpropion Pharmaceuticals Llc
Publication of BR112013015957A2 publication Critical patent/BR112013015957A2/pt
Publication of BR112013015957B1 publication Critical patent/BR112013015957B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
BR112013015957-0A 2010-12-03 2011-12-02 Uso de naltrexona ou um sal farmaceuticamenteaceitável da mesma e bupropiona ou um salfarmaceuticamente aceitável da mesma, composiçãofarmacêutica e kit BR112013015957B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41935410P 2010-12-03 2010-12-03
US61/419,354 2010-12-03
PCT/US2011/063170 WO2012075453A1 (en) 2010-12-03 2011-12-02 Methods for reducing binge or compulsive eating

Publications (2)

Publication Number Publication Date
BR112013015957A2 BR112013015957A2 (pt) 2019-10-29
BR112013015957B1 true BR112013015957B1 (pt) 2021-07-20

Family

ID=46172302

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013015957-0A BR112013015957B1 (pt) 2010-12-03 2011-12-02 Uso de naltrexona ou um sal farmaceuticamenteaceitável da mesma e bupropiona ou um salfarmaceuticamente aceitável da mesma, composiçãofarmacêutica e kit

Country Status (27)

Country Link
US (2) US20130252995A1 (cg-RX-API-DMAC7.html)
EP (1) EP2646011B1 (cg-RX-API-DMAC7.html)
JP (1) JP2014508717A (cg-RX-API-DMAC7.html)
KR (1) KR20140035319A (cg-RX-API-DMAC7.html)
CN (1) CN103298462A (cg-RX-API-DMAC7.html)
AR (2) AR084093A1 (cg-RX-API-DMAC7.html)
AU (3) AU2011336298B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013015957B1 (cg-RX-API-DMAC7.html)
CA (1) CA2819003A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013001565A1 (cg-RX-API-DMAC7.html)
CY (1) CY1119560T1 (cg-RX-API-DMAC7.html)
DK (1) DK2646011T3 (cg-RX-API-DMAC7.html)
ES (1) ES2647232T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20171678T1 (cg-RX-API-DMAC7.html)
HU (1) HUE034641T2 (cg-RX-API-DMAC7.html)
IL (1) IL226483A0 (cg-RX-API-DMAC7.html)
LT (1) LT2646011T (cg-RX-API-DMAC7.html)
MX (1) MX350304B (cg-RX-API-DMAC7.html)
NO (1) NO2646011T3 (cg-RX-API-DMAC7.html)
PL (1) PL2646011T3 (cg-RX-API-DMAC7.html)
PT (1) PT2646011T (cg-RX-API-DMAC7.html)
RS (1) RS56548B1 (cg-RX-API-DMAC7.html)
RU (1) RU2620913C2 (cg-RX-API-DMAC7.html)
SI (1) SI2646011T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201700537T1 (cg-RX-API-DMAC7.html)
TW (2) TWI536986B (cg-RX-API-DMAC7.html)
WO (1) WO2012075453A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2197250C2 (ru) * 2000-10-30 2003-01-27 Соколовский Сергей Ростиславович Способ лечения наркоманий
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
DE602007005402D1 (de) 2006-11-09 2010-04-29 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
GB2447949B (en) * 2007-03-29 2010-03-31 Renasci Consultancy Ltd A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
US8318813B2 (en) * 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
US20100317572A1 (en) * 2007-12-20 2010-12-16 Neurosearch A/S Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity compound
KR102385359B1 (ko) * 2010-11-08 2022-04-11 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료

Also Published As

Publication number Publication date
US20130252995A1 (en) 2013-09-26
WO2012075453A1 (en) 2012-06-07
AU2017202793A1 (en) 2017-05-18
NO2646011T3 (cg-RX-API-DMAC7.html) 2018-01-13
AU2011336298A1 (en) 2013-07-11
PT2646011T (pt) 2017-11-17
CN103298462A (zh) 2013-09-11
CA2819003A1 (en) 2012-06-07
RU2620913C2 (ru) 2017-05-30
HUE034641T2 (en) 2018-02-28
PL2646011T3 (pl) 2018-01-31
KR20140035319A (ko) 2014-03-21
BR112013015957A2 (pt) 2019-10-29
LT2646011T (lt) 2017-11-10
JP2014508717A (ja) 2014-04-10
US20210283126A1 (en) 2021-09-16
SMT201700537T1 (it) 2018-01-11
AU2018203921A1 (en) 2018-06-21
EP2646011B1 (en) 2017-08-16
RS56548B1 (sr) 2018-02-28
HRP20171678T1 (hr) 2017-12-15
IL226483A0 (en) 2013-07-31
TWI536986B (zh) 2016-06-11
DK2646011T3 (da) 2017-11-20
AU2017202793B2 (en) 2018-03-08
TW201228659A (en) 2012-07-16
CL2013001565A1 (es) 2014-04-04
EP2646011A1 (en) 2013-10-09
MX2013006070A (es) 2013-07-29
RU2013127420A (ru) 2015-01-10
CY1119560T1 (el) 2018-03-07
MX350304B (es) 2017-09-04
SI2646011T1 (en) 2018-01-31
TW201735912A (zh) 2017-10-16
AR124497A2 (es) 2023-04-05
AU2011336298B2 (en) 2017-03-02
ES2647232T3 (es) 2017-12-20
AR084093A1 (es) 2013-04-17
EP2646011A4 (en) 2014-04-23

Similar Documents

Publication Publication Date Title
AU2017202793B2 (en) Methods for Reducing Binge or Compulsive Eating
US11033543B2 (en) Methods of providing weight loss therapy in patients with major depression
McElroy et al. Naltrexone/Bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study
Nishioka et al. The concept of aggressive nutrition therapy and clinical indication: a position paper
WO2016167855A1 (en) Combination of albuterol and caffeine as synergistic treatment for obesity or sarcopenia
Gowan et al. Disease state management: Type 2 diabetes in older people living in the community
HK1188148B (en) Methods for reducing binge or compulsive eating
HK1188148A (en) Methods for reducing binge or compulsive eating
Shukla et al. Role of Matra in Ahara and Oushadha
Watkins et al. Physical Health in the Context of Mental Health
Hussar New drugs 2015, part 4
WO2007073134A1 (es) Composiciones farmaceuticas que comprenden sustancias inhibidoras de las lipasas intestinales combinadas con un complejo o-coordinado de dinicotinato de cromo para su uso en el tratamiento y control de la obesidad o sobrepeso
Markowitz Body mass index and disordered eating in adolescent females with type 1 diabetes
Van der Westhuizen Obesity: evidence-based pharmacy practice
Singh Developing Healthy Sleep Habits to Support GLP-1 Medication (Wegovy and Mounjaro) Efficacy
Hecker THE PCCA BLOG
Lord The Effect of a Herbal Formulation on General Well-Being in Overweight and Obese Individuals

Legal Events

Date Code Title Description
B12F Other appeals [chapter 12.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: NALPROPION PHARMACEUTICALS, INC. (US)

B25D Requested change of name of applicant approved

Owner name: NALPROPION PHARMACEUTICALS LLC (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/12/2011, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.002787/2026-62 ORIGEM: 13A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO: 5121793-69.2025.4.02.5101/RJ SUB JUDICE COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: EUROFARMA LABORATORIOS S.A. REU(S): NALPROPION PHARMACEUTICALS LLC. E INSTITUTO NACIONAL DE PROPRIEDADE INDUSTRIAL ? INPI